From the RNA world to the clinic

The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, wi...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Bruce A Sullenger [verfasserIn] Smita Nair

Format:	Artikel
Sprache:	Englisch

Erschienen:	2016

Rechteinformationen:	Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science. © COPYRIGHT 2016 American Association for the Advancement of Science

Schlagwörter:	Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA

Übergeordnetes Werk:	Enthalten in: Science - Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883, 352(2016), 6292, Seite 1417-1420
Übergeordnetes Werk:	volume:352 ; year:2016 ; number:6292 ; pages:1417-1420

Links:	Volltext Link aufrufen Link aufrufen

DOI / URN:	10.1126/science.aad8709

Katalog-ID:	OLC1977627870

Internformat


LEADER	01000caa a2200265 4500
001	OLC1977627870
003	DE-627
005	20230714195343.0
007	tu
008	160719s2016 xx \|\|\|\|\| 00\| \|\|eng c
024	7		\|a 10.1126/science.aad8709 \|2 doi
028	5	2	\|a PQ20160719
035			\|a (DE-627)OLC1977627870
035			\|a (DE-599)GBVOLC1977627870
035			\|a (PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710
035			\|a (KEY)0063888920160000352629201417fromthernaworldtotheclinic
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 500 \|q DNB
084			\|a LING \|2 fid
100	0		\|a Bruce A Sullenger \|e verfasserin \|4 aut
245	1	0	\|a From the RNA world to the clinic
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a ohne Hilfsmittel zu benutzen \|b n \|2 rdamedia
338			\|a Band \|b nc \|2 rdacarrier
520			\|a The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.
540			\|a Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science.
540			\|a © COPYRIGHT 2016 American Association for the Advancement of Science
650		4	\|a Cancer Vaccines - therapeutic use
650		4	\|a Immunotherapy - methods
650		4	\|a Cancer Vaccines - genetics
650		4	\|a RNA, Small Interfering - genetics
650		4	\|a RNA, Long Noncoding - genetics
650		4	\|a Biological Therapy - methods
650		4	\|a RNA, Messenger - genetics
650		4	\|a Proteins - antagonists & inhibitors
650		4	\|a RNA
700	0		\|a Smita Nair \|4 oth
773	0	8	\|i Enthalten in \|t Science \|d Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883 \|g 352(2016), 6292, Seite 1417-1420 \|w (DE-627)12931482X \|w (DE-600)128410-1 \|w (DE-576)014533189 \|x 0036-8075 \|7 nnns
773	1	8	\|g volume:352 \|g year:2016 \|g number:6292 \|g pages:1417-1420
856	4	1	\|u http://dx.doi.org/10.1126/science.aad8709 \|3 Volltext
856	4	2	\|u http://www.ncbi.nlm.nih.gov/pubmed/27313039
856	4	2	\|u http://search.proquest.com/docview/1799273986
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-LING
912			\|a SSG-OLC-PHY
912			\|a SSG-OLC-CHE
912			\|a SSG-OLC-MAT
912			\|a SSG-OLC-FOR
912			\|a SSG-OLC-SPO
912			\|a SSG-OLC-IBL
912			\|a SSG-OLC-PHA
912			\|a SSG-OLC-DE-84
912			\|a SSG-OPC-FOR
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_21
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_30
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_47
912			\|a GBV_ILN_55
912			\|a GBV_ILN_59
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_92
912			\|a GBV_ILN_101
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_131
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_179
912			\|a GBV_ILN_181
912			\|a GBV_ILN_211
912			\|a GBV_ILN_252
912			\|a GBV_ILN_259
912			\|a GBV_ILN_290
912			\|a GBV_ILN_600
912			\|a GBV_ILN_601
912			\|a GBV_ILN_647
912			\|a GBV_ILN_754
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2012
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2120
912			\|a GBV_ILN_2121
912			\|a GBV_ILN_2173
912			\|a GBV_ILN_2219
912			\|a GBV_ILN_2221
912			\|a GBV_ILN_2279
912			\|a GBV_ILN_2286
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4036
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4219
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4277
912			\|a GBV_ILN_4302
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4310
912			\|a GBV_ILN_4314
912			\|a GBV_ILN_4317
912			\|a GBV_ILN_4318
912			\|a GBV_ILN_4320
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 352 \|j 2016 \|e 6292 \|h 1417-1420

Indexfelder

author_variant	b a s bas
matchkey_str	article:00368075:2016----::rmhraoltt
hierarchy_sort_str	2016
publishDate	2016
allfields	10.1126/science.aad8709 doi PQ20160719 (DE-627)OLC1977627870 (DE-599)GBVOLC1977627870 (PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710 (KEY)0063888920160000352629201417fromthernaworldtotheclinic DE-627 ger DE-627 rakwb eng 500 DNB LING fid Bruce A Sullenger verfasserin aut From the RNA world to the clinic 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents. Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science. © COPYRIGHT 2016 American Association for the Advancement of Science Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA Smita Nair oth Enthalten in Science Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883 352(2016), 6292, Seite 1417-1420 (DE-627)12931482X (DE-600)128410-1 (DE-576)014533189 0036-8075 nnns volume:352 year:2016 number:6292 pages:1417-1420 http://dx.doi.org/10.1126/science.aad8709 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27313039 http://search.proquest.com/docview/1799273986 GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-LING SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-FOR SSG-OLC-SPO SSG-OLC-IBL SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-FOR GBV_ILN_11 GBV_ILN_20 GBV_ILN_21 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_47 GBV_ILN_55 GBV_ILN_59 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_92 GBV_ILN_101 GBV_ILN_110 GBV_ILN_120 GBV_ILN_131 GBV_ILN_170 GBV_ILN_171 GBV_ILN_179 GBV_ILN_181 GBV_ILN_211 GBV_ILN_252 GBV_ILN_259 GBV_ILN_290 GBV_ILN_600 GBV_ILN_601 GBV_ILN_647 GBV_ILN_754 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2012 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2116 GBV_ILN_2120 GBV_ILN_2121 GBV_ILN_2173 GBV_ILN_2219 GBV_ILN_2221 GBV_ILN_2279 GBV_ILN_2286 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4036 GBV_ILN_4125 GBV_ILN_4219 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4302 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4310 GBV_ILN_4314 GBV_ILN_4317 GBV_ILN_4318 GBV_ILN_4320 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4700 AR 352 2016 6292 1417-1420
spelling	10.1126/science.aad8709 doi PQ20160719 (DE-627)OLC1977627870 (DE-599)GBVOLC1977627870 (PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710 (KEY)0063888920160000352629201417fromthernaworldtotheclinic DE-627 ger DE-627 rakwb eng 500 DNB LING fid Bruce A Sullenger verfasserin aut From the RNA world to the clinic 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents. Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science. © COPYRIGHT 2016 American Association for the Advancement of Science Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA Smita Nair oth Enthalten in Science Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883 352(2016), 6292, Seite 1417-1420 (DE-627)12931482X (DE-600)128410-1 (DE-576)014533189 0036-8075 nnns volume:352 year:2016 number:6292 pages:1417-1420 http://dx.doi.org/10.1126/science.aad8709 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27313039 http://search.proquest.com/docview/1799273986 GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-LING SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-FOR SSG-OLC-SPO SSG-OLC-IBL SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-FOR GBV_ILN_11 GBV_ILN_20 GBV_ILN_21 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_47 GBV_ILN_55 GBV_ILN_59 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_92 GBV_ILN_101 GBV_ILN_110 GBV_ILN_120 GBV_ILN_131 GBV_ILN_170 GBV_ILN_171 GBV_ILN_179 GBV_ILN_181 GBV_ILN_211 GBV_ILN_252 GBV_ILN_259 GBV_ILN_290 GBV_ILN_600 GBV_ILN_601 GBV_ILN_647 GBV_ILN_754 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2012 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2116 GBV_ILN_2120 GBV_ILN_2121 GBV_ILN_2173 GBV_ILN_2219 GBV_ILN_2221 GBV_ILN_2279 GBV_ILN_2286 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4036 GBV_ILN_4125 GBV_ILN_4219 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4302 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4310 GBV_ILN_4314 GBV_ILN_4317 GBV_ILN_4318 GBV_ILN_4320 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4700 AR 352 2016 6292 1417-1420
allfields_unstemmed	10.1126/science.aad8709 doi PQ20160719 (DE-627)OLC1977627870 (DE-599)GBVOLC1977627870 (PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710 (KEY)0063888920160000352629201417fromthernaworldtotheclinic DE-627 ger DE-627 rakwb eng 500 DNB LING fid Bruce A Sullenger verfasserin aut From the RNA world to the clinic 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents. Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science. © COPYRIGHT 2016 American Association for the Advancement of Science Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA Smita Nair oth Enthalten in Science Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883 352(2016), 6292, Seite 1417-1420 (DE-627)12931482X (DE-600)128410-1 (DE-576)014533189 0036-8075 nnns volume:352 year:2016 number:6292 pages:1417-1420 http://dx.doi.org/10.1126/science.aad8709 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27313039 http://search.proquest.com/docview/1799273986 GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-LING SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-FOR SSG-OLC-SPO SSG-OLC-IBL SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-FOR GBV_ILN_11 GBV_ILN_20 GBV_ILN_21 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_47 GBV_ILN_55 GBV_ILN_59 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_92 GBV_ILN_101 GBV_ILN_110 GBV_ILN_120 GBV_ILN_131 GBV_ILN_170 GBV_ILN_171 GBV_ILN_179 GBV_ILN_181 GBV_ILN_211 GBV_ILN_252 GBV_ILN_259 GBV_ILN_290 GBV_ILN_600 GBV_ILN_601 GBV_ILN_647 GBV_ILN_754 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2012 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2116 GBV_ILN_2120 GBV_ILN_2121 GBV_ILN_2173 GBV_ILN_2219 GBV_ILN_2221 GBV_ILN_2279 GBV_ILN_2286 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4036 GBV_ILN_4125 GBV_ILN_4219 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4302 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4310 GBV_ILN_4314 GBV_ILN_4317 GBV_ILN_4318 GBV_ILN_4320 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4700 AR 352 2016 6292 1417-1420
allfieldsGer	10.1126/science.aad8709 doi PQ20160719 (DE-627)OLC1977627870 (DE-599)GBVOLC1977627870 (PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710 (KEY)0063888920160000352629201417fromthernaworldtotheclinic DE-627 ger DE-627 rakwb eng 500 DNB LING fid Bruce A Sullenger verfasserin aut From the RNA world to the clinic 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents. Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science. © COPYRIGHT 2016 American Association for the Advancement of Science Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA Smita Nair oth Enthalten in Science Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883 352(2016), 6292, Seite 1417-1420 (DE-627)12931482X (DE-600)128410-1 (DE-576)014533189 0036-8075 nnns volume:352 year:2016 number:6292 pages:1417-1420 http://dx.doi.org/10.1126/science.aad8709 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27313039 http://search.proquest.com/docview/1799273986 GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-LING SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-FOR SSG-OLC-SPO SSG-OLC-IBL SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-FOR GBV_ILN_11 GBV_ILN_20 GBV_ILN_21 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_47 GBV_ILN_55 GBV_ILN_59 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_92 GBV_ILN_101 GBV_ILN_110 GBV_ILN_120 GBV_ILN_131 GBV_ILN_170 GBV_ILN_171 GBV_ILN_179 GBV_ILN_181 GBV_ILN_211 GBV_ILN_252 GBV_ILN_259 GBV_ILN_290 GBV_ILN_600 GBV_ILN_601 GBV_ILN_647 GBV_ILN_754 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2012 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2116 GBV_ILN_2120 GBV_ILN_2121 GBV_ILN_2173 GBV_ILN_2219 GBV_ILN_2221 GBV_ILN_2279 GBV_ILN_2286 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4036 GBV_ILN_4125 GBV_ILN_4219 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4302 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4310 GBV_ILN_4314 GBV_ILN_4317 GBV_ILN_4318 GBV_ILN_4320 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4700 AR 352 2016 6292 1417-1420
allfieldsSound	10.1126/science.aad8709 doi PQ20160719 (DE-627)OLC1977627870 (DE-599)GBVOLC1977627870 (PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710 (KEY)0063888920160000352629201417fromthernaworldtotheclinic DE-627 ger DE-627 rakwb eng 500 DNB LING fid Bruce A Sullenger verfasserin aut From the RNA world to the clinic 2016 Text txt rdacontent ohne Hilfsmittel zu benutzen n rdamedia Band nc rdacarrier The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents. Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science. © COPYRIGHT 2016 American Association for the Advancement of Science Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA Smita Nair oth Enthalten in Science Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883 352(2016), 6292, Seite 1417-1420 (DE-627)12931482X (DE-600)128410-1 (DE-576)014533189 0036-8075 nnns volume:352 year:2016 number:6292 pages:1417-1420 http://dx.doi.org/10.1126/science.aad8709 Volltext http://www.ncbi.nlm.nih.gov/pubmed/27313039 http://search.proquest.com/docview/1799273986 GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-LING SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-FOR SSG-OLC-SPO SSG-OLC-IBL SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-FOR GBV_ILN_11 GBV_ILN_20 GBV_ILN_21 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_47 GBV_ILN_55 GBV_ILN_59 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_92 GBV_ILN_101 GBV_ILN_110 GBV_ILN_120 GBV_ILN_131 GBV_ILN_170 GBV_ILN_171 GBV_ILN_179 GBV_ILN_181 GBV_ILN_211 GBV_ILN_252 GBV_ILN_259 GBV_ILN_290 GBV_ILN_600 GBV_ILN_601 GBV_ILN_647 GBV_ILN_754 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2012 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2116 GBV_ILN_2120 GBV_ILN_2121 GBV_ILN_2173 GBV_ILN_2219 GBV_ILN_2221 GBV_ILN_2279 GBV_ILN_2286 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4036 GBV_ILN_4125 GBV_ILN_4219 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4302 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4310 GBV_ILN_4314 GBV_ILN_4317 GBV_ILN_4318 GBV_ILN_4320 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4700 AR 352 2016 6292 1417-1420
language	English
source	Enthalten in Science 352(2016), 6292, Seite 1417-1420 volume:352 year:2016 number:6292 pages:1417-1420
sourceStr	Enthalten in Science 352(2016), 6292, Seite 1417-1420 volume:352 year:2016 number:6292 pages:1417-1420
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA
dewey-raw	500
isfreeaccess_bool	false
container_title	Science
authorswithroles_txt_mv	Bruce A Sullenger @@aut@@ Smita Nair @@oth@@
publishDateDaySort_date	2016-01-01T00:00:00Z
hierarchy_top_id	12931482X
dewey-sort	3500
id	OLC1977627870
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1977627870</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230714195343.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">160719s2016 xx \|\|\|\|\| 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1126/science.aad8709</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20160719</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1977627870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1977627870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0063888920160000352629201417fromthernaworldtotheclinic</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bruce A Sullenger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">From the RNA world to the clinic</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science.</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">© COPYRIGHT 2016 American Association for the Advancement of Science</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Vaccines - therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotherapy - methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Vaccines - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA, Small Interfering - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA, Long Noncoding - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological Therapy - methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA, Messenger - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proteins - antagonists & inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Smita Nair</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Science</subfield><subfield code="d">Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883</subfield><subfield code="g">352(2016), 6292, Seite 1417-1420</subfield><subfield code="w">(DE-627)12931482X</subfield><subfield code="w">(DE-600)128410-1</subfield><subfield code="w">(DE-576)014533189</subfield><subfield code="x">0036-8075</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:352</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:6292</subfield><subfield code="g">pages:1417-1420</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1126/science.aad8709</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://www.ncbi.nlm.nih.gov/pubmed/27313039</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://search.proquest.com/docview/1799273986</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-MAT</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-FOR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-SPO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-IBL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_47</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_55</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_59</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_92</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_131</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_179</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_181</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_259</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_290</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_600</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_601</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_647</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_754</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2173</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2221</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2279</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2286</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4036</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4302</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4310</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4314</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4317</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4318</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4320</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">352</subfield><subfield code="j">2016</subfield><subfield code="e">6292</subfield><subfield code="h">1417-1420</subfield></datafield></record></collection>
author	Bruce A Sullenger
spellingShingle	Bruce A Sullenger ddc 500 fid LING misc Cancer Vaccines - therapeutic use misc Immunotherapy - methods misc Cancer Vaccines - genetics misc RNA, Small Interfering - genetics misc RNA, Long Noncoding - genetics misc Biological Therapy - methods misc RNA, Messenger - genetics misc Proteins - antagonists & inhibitors misc RNA From the RNA world to the clinic
authorStr	Bruce A Sullenger
ppnlink_with_tag_str_mv	@@773@@(DE-627)12931482X
format	Article
dewey-ones	500 - Natural sciences & mathematics
delete_txt_mv	keep
author_role	aut
collection	OLC
remote_str	false
illustrated	Not Illustrated
issn	0036-8075
topic_title	500 DNB LING fid From the RNA world to the clinic Cancer Vaccines - therapeutic use Immunotherapy - methods Cancer Vaccines - genetics RNA, Small Interfering - genetics RNA, Long Noncoding - genetics Biological Therapy - methods RNA, Messenger - genetics Proteins - antagonists & inhibitors RNA
topic	ddc 500 fid LING misc Cancer Vaccines - therapeutic use misc Immunotherapy - methods misc Cancer Vaccines - genetics misc RNA, Small Interfering - genetics misc RNA, Long Noncoding - genetics misc Biological Therapy - methods misc RNA, Messenger - genetics misc Proteins - antagonists & inhibitors misc RNA
topic_unstemmed	ddc 500 fid LING misc Cancer Vaccines - therapeutic use misc Immunotherapy - methods misc Cancer Vaccines - genetics misc RNA, Small Interfering - genetics misc RNA, Long Noncoding - genetics misc Biological Therapy - methods misc RNA, Messenger - genetics misc Proteins - antagonists & inhibitors misc RNA
topic_browse	ddc 500 fid LING misc Cancer Vaccines - therapeutic use misc Immunotherapy - methods misc Cancer Vaccines - genetics misc RNA, Small Interfering - genetics misc RNA, Long Noncoding - genetics misc Biological Therapy - methods misc RNA, Messenger - genetics misc Proteins - antagonists & inhibitors misc RNA
format_facet	Aufsätze Gedruckte Aufsätze
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	nc
author2_variant	s n sn
hierarchy_parent_title	Science
hierarchy_parent_id	12931482X
dewey-tens	500 - Science
hierarchy_top_title	Science
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)12931482X (DE-600)128410-1 (DE-576)014533189
title	From the RNA world to the clinic
ctrlnum	(DE-627)OLC1977627870 (DE-599)GBVOLC1977627870 (PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710 (KEY)0063888920160000352629201417fromthernaworldtotheclinic
title_full	From the RNA world to the clinic
author_sort	Bruce A Sullenger
journal	Science
journalStr	Science
lang_code	eng
isOA_bool	false
dewey-hundreds	500 - Science
recordtype	marc
publishDateSort	2016
contenttype_str_mv	txt
container_start_page	1417
author_browse	Bruce A Sullenger
container_volume	352
class	500 DNB LING fid
format_se	Aufsätze
author-letter	Bruce A Sullenger
doi_str_mv	10.1126/science.aad8709
dewey-full	500
title_sort	from the rna world to the clinic
title_auth	From the RNA world to the clinic
abstract	The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.
abstractGer	The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.
abstract_unstemmed	The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_OLC FID-LING SSG-OLC-PHY SSG-OLC-CHE SSG-OLC-MAT SSG-OLC-FOR SSG-OLC-SPO SSG-OLC-IBL SSG-OLC-PHA SSG-OLC-DE-84 SSG-OPC-FOR GBV_ILN_11 GBV_ILN_20 GBV_ILN_21 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_47 GBV_ILN_55 GBV_ILN_59 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_92 GBV_ILN_101 GBV_ILN_110 GBV_ILN_120 GBV_ILN_131 GBV_ILN_170 GBV_ILN_171 GBV_ILN_179 GBV_ILN_181 GBV_ILN_211 GBV_ILN_252 GBV_ILN_259 GBV_ILN_290 GBV_ILN_600 GBV_ILN_601 GBV_ILN_647 GBV_ILN_754 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2012 GBV_ILN_2015 GBV_ILN_2018 GBV_ILN_2020 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2116 GBV_ILN_2120 GBV_ILN_2121 GBV_ILN_2173 GBV_ILN_2219 GBV_ILN_2221 GBV_ILN_2279 GBV_ILN_2286 GBV_ILN_4012 GBV_ILN_4035 GBV_ILN_4036 GBV_ILN_4125 GBV_ILN_4219 GBV_ILN_4251 GBV_ILN_4277 GBV_ILN_4302 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4310 GBV_ILN_4314 GBV_ILN_4317 GBV_ILN_4318 GBV_ILN_4320 GBV_ILN_4328 GBV_ILN_4333 GBV_ILN_4700
container_issue	6292
title_short	From the RNA world to the clinic
url	http://dx.doi.org/10.1126/science.aad8709 http://www.ncbi.nlm.nih.gov/pubmed/27313039 http://search.proquest.com/docview/1799273986
remote_bool	false
author2	Smita Nair
author2Str	Smita Nair
ppnlink	12931482X
mediatype_str_mv	n
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth
doi_str	10.1126/science.aad8709
up_date	2024-07-03T18:57:44.395Z
_version_	1803585390531051520
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a2200265 4500</leader><controlfield tag="001">OLC1977627870</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230714195343.0</controlfield><controlfield tag="007">tu</controlfield><controlfield tag="008">160719s2016 xx \|\|\|\|\| 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1126/science.aad8709</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">PQ20160719</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)OLC1977627870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)GBVOLC1977627870</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(PRQ)c1799-99ff2cb9fbbe77abdc5c7d21f2ad5cad6263c3e0b4ede8b89c8ac704464fac710</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(KEY)0063888920160000352629201417fromthernaworldtotheclinic</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">500</subfield><subfield code="q">DNB</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">LING</subfield><subfield code="2">fid</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bruce A Sullenger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">From the RNA world to the clinic</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">ohne Hilfsmittel zu benutzen</subfield><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Band</subfield><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The study of RNA has continually emphasized the structural and functional versatility of RNA molecules. This versatility has inspired translational and clinical researchers to explore the utility of RNA-based therapeutic agents for a wide variety of medical applications. Several RNA therapeutics, with diverse modes of action, are being evaluated in large late-stage clinical trials, and many more are in early clinical development. Hundreds of patients are enrolled in large trials testing messenger RNAs to combat cancer, small interfering RNAs to treat renal and hepatic disorders, and aptamers to combat ocular and cardiovascular disease. Results from these studies are generating considerable interest among the biomedical community and the public and will be important for the future development of this emerging class of therapeutic agents.</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">Nutzungsrecht: Copyright © 2016, American Association for the Advancement of Science.</subfield></datafield><datafield tag="540" ind1=" " ind2=" "><subfield code="a">© COPYRIGHT 2016 American Association for the Advancement of Science</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Vaccines - therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunotherapy - methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Vaccines - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA, Small Interfering - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA, Long Noncoding - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological Therapy - methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA, Messenger - genetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Proteins - antagonists & inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">RNA</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Smita Nair</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Science</subfield><subfield code="d">Washington, DC : AAAS, American Assoc. for the Advancement of Science, 1883</subfield><subfield code="g">352(2016), 6292, Seite 1417-1420</subfield><subfield code="w">(DE-627)12931482X</subfield><subfield code="w">(DE-600)128410-1</subfield><subfield code="w">(DE-576)014533189</subfield><subfield code="x">0036-8075</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:352</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:6292</subfield><subfield code="g">pages:1417-1420</subfield></datafield><datafield tag="856" ind1="4" ind2="1"><subfield code="u">http://dx.doi.org/10.1126/science.aad8709</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://www.ncbi.nlm.nih.gov/pubmed/27313039</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">http://search.proquest.com/docview/1799273986</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_OLC</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-LING</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-CHE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-MAT</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-FOR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-SPO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-IBL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-DE-84</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-FOR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_47</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_55</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_59</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_92</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_101</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_131</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_179</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_181</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_211</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_252</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_259</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_290</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_600</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_601</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_647</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_754</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2121</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2173</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2221</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2279</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2286</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4036</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4219</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4277</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4302</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4310</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4314</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4317</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4318</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4320</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4328</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">352</subfield><subfield code="j">2016</subfield><subfield code="e">6292</subfield><subfield code="h">1417-1420</subfield></datafield></record></collection>
score	7.400732

Nicht das Richtige dabei?

Schreiben Sie uns!

From the RNA world to the clinic

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?